Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 7.4.2.1 - ABC-type polar-amino-acid transporter

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
abc-type polar-amino-acid transporter deficiency
A global Slc7a7 knockout mouse model demonstrates characteristic phenotypes of human lysinuric protein intolerance.
Participation of an extracellular deaminase in amino acid utilization by Neurospora crassa.
Acid-Base Imbalance
Regulation of expression of the SN1 transporter during renal adaptation to chronic metabolic acidosis in rats.
Acidosis
Regulation of expression of the SN1 transporter during renal adaptation to chronic metabolic acidosis in rats.
Regulation of renal amino acid transporters during metabolic acidosis.
Acquired Immunodeficiency Syndrome
Reduced expression of excitatory amino acid transporter 2 and diffuse microglial activation in the cerebral cortex in AIDS cases with or without HIV encephalitis.
Adenocarcinoma
High expression of L-type amino acid transporter 1 (LAT1) predicts poor prognosis in pancreatic ductal adenocarcinomas.
High expression of L-type amino acid transporter 1 as a prognostic marker in bile duct adenocarcinomas.
Prognostic significance of l-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in stage I pulmonary adenocarcinoma.
Adenocarcinoma of Lung
Clinical significance of coexpression of L-type amino acid transporter 1 (LAT1) and ASC amino acid transporter 2 (ASCT2) in lung adenocarcinoma.
Alzheimer Disease
Aberrant detergent-insoluble excitatory amino acid transporter 2 accumulates in Alzheimer disease.
Aberrant expression of the glutamate transporter excitatory amino acid transporter 1 (EAAT1) in Alzheimer's disease.
Alzheimer's Disease Phenotype or Inflammatory Insult Does Not Alter Function of L-Type Amino Acid Transporter 1 in Mouse Blood-Brain Barrier and Primary Astrocytes.
Chemical hypoxia facilitates alternative splicing of EAAT2 in presymptomatic APP23 transgenic mice.
Excitatory amino acid transporter EAAT-2 in tangle-bearing neurons in Alzheimer's disease.
Manganese-induced reactive oxygen species activate I?B kinase to upregulate YY1 and impair glutamate transporter EAAT2 function in human astrocytes in vitro.
Amyotrophic Lateral Sclerosis
Change in Cationic Amino Acid Transport System and Effect of Lysine Pretreatment on Inflammatory State in Amyotrophic Lateral Sclerosis Cell Model.
Excitatory amino acid transporter 1 and 2 immunoreactivity in the spinal cord in amyotrophic lateral sclerosis.
Induction of Nrf2 and xCT are involved in the action of the neuroprotective antibiotic ceftriaxone in vitro.
Anhedonia
Increased Vulnerability to Depressive-Like Behavior of Mice with Decreased Expression of VGLUT1.
arginase deficiency
A new metabolic disorder in human cationic amino acid transporter-2 that mimics arginase 1 deficiency in newborn screening.
Asthma
Dissection of experimental asthma with DNA microarray analysis identifies arginase in asthma pathogenesis.
Ataxia
A point mutation associated with episodic ataxia 6 increases glutamate transporter anion currents.
Disruption of an EAAT-Mediated Chloride Channel in a Drosophila Model of Ataxia.
Increased glutamate transporter-associated anion currents cause glial apoptosis in episodic ataxia 6.
Late-onset episodic ataxia associated with SLC1A3 mutation.
Biliary Tract Neoplasms
Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in biliary tract cancer.
Brain Diseases
Identification of a group of brominated flame retardants as novel androgen receptor antagonists and potential neuronal and endocrine disrupters.
Neuromyelitis optica - an update: 2007-2009.
Brain Injuries
Ceftriaxone alleviates early brain injury after subarachnoid hemorrhage by increasing excitatory amino acid transporter 2 expression via the PI3K/Akt/NF-?B signaling pathway.
Brain Injuries, Traumatic
The expression of excitatory amino acid transporter 2 in traumatic brain injury.
Brain Ischemia
Ischemia-induced upregulation of excitatory amino acid transport sites.
Brain Neoplasms
Arginine auxotrophic gene signature in paediatric sarcomas and brain tumours provides a viable target for arginine depletion therapies.
New fluoroethyl phenylalanine analogues as potential LAT1-targeting PET tracers for glioblastoma.
Breast Neoplasms
Aryl hydrocarbon receptor (AHR) regulation of L-Type Amino Acid Transporter 1 (LAT-1) expression in MCF-7 and MDA-MB-231 breast cancer cells.
Conditionally immortalized syncytiotrophoblast cell lines as new tools for study of the blood-placenta barrier.
Correlation of L-type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis.
Deletion of the amino acid transporter Slc6a14 suppresses tumor growth in spontaneous mouse models of breast cancer.
Deletion of the amino acid transporter Slc6a14 suppresses tumour growth in spontaneous mouse models of breast cancer.
Increased expression of glutamine transporter SNAT2/SLC38A2 promotes glutamine dependence and oxidative stress resistance, and is associated with worse prognosis in triple-negative breast cancer.
L-type amino acid transporter 1 is associated with chemoresistance in breast cancer via the promotion of amino acid metabolism.
PET Imaging of L-Type Amino Acid Transporter (LAT1) and Cystine-Glutamate Antiporter (xc-) with [18F]FDOPA and [18F]FSPG in Breast Cancer Models.
Potential Biomarker of L-type Amino Acid Transporter 1 in Breast Cancer Progression.
Prognostic values of L-type amino acid transporter 1 and CD98hc expression in breast cancer.
Proteomic profiling of breast cancer metabolism identifies SHMT2 and ASCT2 as prognostic factors.
Quantitative atlas of blood-brain barrier transporters, receptors, and tight junction proteins in rats and common marmoset.
SLC6A14 (ATB0,+), a highly concentrative and broad-specific amino acid transporter, is a novel and effective drug target for treatment of estrogen receptor-positive breast cancer.
Synthesis of (99m)Tc-EC-AMT as an imaging probe for amino acid transporter systems in breast cancer.
Targeting Amino Acid Metabolic Reprogramming via L-Type Amino Acid Transporter 1 (LAT1) for Endocrine-Resistant Breast Cancer.
Taxol induced apoptosis regulates amino acid transport in breast cancer cells.
The Adipose Tissue-Derived Secretome (ADS) in Obesity Uniquely Induces L-Type Amino Acid Transporter 1 (LAT1) and mTOR Signaling in Estrogen-Receptor-Positive Breast Cancer Cells.
The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours.
Tyrosine-Chlorambucil Conjugates Facilitate Cellular Uptake through L-Type Amino Acid Transporter 1 (LAT1) in Human Breast Cancer Cell Line MCF-7.
Carcinogenesis
Divergent expression of L-type amino acid transporter 1 during uterine cervical carcinogenesis.
Enhanced tumor growth elicited by L-type amino acid transporter 1 in human malignant glioma cells.
L-type amino acid transporter 1 expression in esophageal carcinogenesis according to WHO and Japanese classifications of intraepithelial neoplasia.
Overexpression of SLC7A7 predicts poor progression-free and overall survival in patients with glioblastoma.
Systemic muscle wasting and coordinated tumour response drive tumourigenesis.
Carcinoma
Characterization of the system L amino acid transporter in T24 human bladder carcinoma cells.
Clinicopathological Significance of L-type Amino Acid Transporter 1 (LAT1) Expression in Patients with Adenoid Cystic Carcinoma.
Diagnostic usefulness of (18)F-FAMT PET and L-type amino acid transporter 1 (LAT1) expression in oral squamous cell carcinoma.
Expression of a highly conserved oncofetal gene, TA1/E16, in human colon carcinoma and other primary cancers: homology to Schistosoma mansoni amino acid permease and Caenorhabditis elegans gene products.
Expression of amino acid transporter (LAT1 and 4F2hc) in pulmonary pleomorphic carcinoma.
Expression of Amino Acid Transporters (LAT1 and ASCT2) in Patients with Stage III/IV Laryngeal Squamous Cell Carcinoma.
Expression of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (4F2hc) in oral squamous cell carcinoma and its precusor lesions.
Expression of L-type amino acid transporter 1 (LAT1) in esophageal carcinoma.
Expression of L-type amino acid transporter 1 as a molecular target for prognostic and therapeutic indicators in bladder carcinoma.
Expression profile of the amino acid transporters SLC7A5, SLC7A7, SLC7A8 and the enzyme TDO2 in basal cell carcinoma.
Gene expression profiles in T24 human bladder carcinoma cells by inhibiting an L-type amino acid transporter, LAT1.
Increased expression of system large amino acid transporter (LAT)-1 mRNA is associated with invasive potential and unfavorable prognosis of human clear cell renal cell carcinoma.
L-Type amino acid transporter 1 (LAT1) expression in lymph node metastasis of gastric carcinoma: Its correlation with size of metastatic lesion and Ki-67 labeling.
Preclinical characterization of (18)F-D-FPHCys, a new amino acid-based PET tracer.
Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in early stage squamous cell carcinoma of the lung.
Relationship between [(14)C]MeAIB uptake and amino acid transporter family gene expression levels or proliferative activity in a pilot study in human carcinoma cells: Comparison with [(3)H]methionine uptake.
System L amino acid transporter inhibitor enhances anti-tumor activity of cisplatin in a head and neck squamous cell carcinoma cell line.
Ultrastructural immunohistochemical study of L-type amino acid transporter 1-4F2 heavy chain in tumor microvasculatures of N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) induced rat bladder carcinoma.
Up-regulation of the amino acid transporter ATB(0,+) (SLC6A14) in carcinoma of the cervix.
Carcinoma, Adenoid Cystic
Clinicopathological Significance of L-type Amino Acid Transporter 1 (LAT1) Expression in Patients with Adenoid Cystic Carcinoma.
Carcinoma, Basal Cell
Expression profile of the amino acid transporters SLC7A5, SLC7A7, SLC7A8 and the enzyme TDO2 in basal cell carcinoma.
Carcinoma, Endometrioid
L-type Amino Acid Transporter 1 Expression Increases in Well-Differentiated but Decreases in Poorly Differentiated Endometrial Endometrioid Adenocarcinoma and Shows an Inverse Correlation With p53 Expression.
Carcinoma, Hepatocellular
Activation of a system A amino acid transporter, ATA1/SLC38A1, in human hepatocellular carcinoma and preneoplastic liver tissues.
Adaptive regulation of the cationic amino acid transporter-1 (Cat-1) in Fao cells.
Analysis of L-type amino acid transporter in canine hepatocellular carcinoma.
Expression of amino acid transporters (LAT1, ASCT2 and xCT) as clinical significance in hepatocellular carcinoma.
Inducible antisense RNA targeting amino acid transporter ATB0/ASCT2 elicits apoptosis in human hepatoma cells.
Molecular and functional analysis of glutamine uptake in human hepatoma and liver-derived cells.
Primary structure, functional characteristics and tissue expression pattern of human ATA2, a subtype of amino acid transport system A.
SLC6A19 is a novel putative gene, induced by dioxins via AhR in human hepatoma HepG2 cells.
Stress-induced reversal of microRNA repression and mRNA P-body localization in human cells.
The impact of L-type amino acid transporter 1 (LAT1) in human hepatocellular carcinoma.
Carcinoma, Non-Small-Cell Lung
Amino acid transporter SLC38A3 promotes metastasis of non-small cell lung cancer cells by activating PDK1.
Comparison of L-type amino acid transporter 1 expression and L-[3-18F]-?-methyl tyrosine uptake in outcome of non-small cell lung cancer.
Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer.
L-type amino acid transporter 1 expression is a prognostic marker in patients with surgically resected stage I non-small cell lung cancer.
Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in surgically resectable stage III non-small cell lung cancer.
Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer.
Relationship between LAT1 expression and response to platinum-based chemotherapy in non-small cell lung cancer patients with postoperative recurrence.
SLC7A7 is a prognostic biomarker correlated with immune infiltrates in non-small cell lung cancer.
Carcinoma, Ovarian Epithelial
Properties of L-type amino acid transporter 1 in epidermal ovarian cancer.
Carcinoma, Renal Cell
Increased expression of system large amino acid transporter (LAT)-1 mRNA is associated with invasive potential and unfavorable prognosis of human clear cell renal cell carcinoma.
Carcinoma, Squamous Cell
Amino acid transport system L is differently expressed in human normal oral keratinocytes and human oral cancer cells.
Expression and functional characterization of the system L amino acid transporter in KB human oral epidermoid carcinoma cells.
Preclinical characterization of (18)F-D-FPHCys, a new amino acid-based PET tracer.
Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in early stage squamous cell carcinoma of the lung.
System L amino acid transporter inhibitor enhances anti-tumor activity of cisplatin in a head and neck squamous cell carcinoma cell line.
Cardiomegaly
Expression and activity of the glutamate transporter EAAT2 in cardiac hypertrophy: implications for ischaemia reperfusion injury.
Cataract
Dysfunctional LAT2 Amino Acid Transporter Is Associated With Cataract in Mouse and Humans.
Lenticular levels of amino acids and free UV filters differ significantly between normals and cataract patients.
Cerebral Infarction
Neuroprotection of rhGLP-1 in diabetic rats with cerebral ischemia/reperfusion injury via regulation of oxidative stress, EAAT2, and apoptosis.
Chagas Disease
Evaluation of proline analogs as trypanocidal agents through the inhibition of a Trypanosoma cruzi proline transporter.
Cholangiocarcinoma
Increase in L-type amino acid transporter 1 expression during cholangiocarcinogenesis caused by liver fluke infection and its prognostic significance.
Inhibition of l-type amino acid transporter 1 activity as a new therapeutic target for cholangiocarcinoma treatment.
Choriocarcinoma
Involvement of l-type amino acid transporter 1 in the transport of gabapentin into human placental choriocarcinoma cells.
L-type amino acid transporter 1 promotes proliferation and invasion of human chorionic trophoblast and choriocarcinoma cells through mTORC1.
Regulation of amino acid transporters by adenoviral-mediated human insulin-like growth factor-1 in a mouse model of placental insufficiency in vivo and the human trophoblast line BeWo in vitro.
Tyrosine phosphorylation-and epidermal growth factor-dependent regulation of the sodium-coupled amino acid transporter B0 in the human placental choriocarcinoma cell line JAR.
Cleft Palate
A shared vesicular carrier allows synaptic corelease of GABA and glycine.
Coccidiosis
Impacts of increasing challenge with Eimeria maxima on the growth performance and gene expression of biomarkers associated with intestinal integrity and nutrient transporters.
Colitis
Deletion of cationic amino acid transporter 2 exacerbates dextran sulfate sodium colitis and leads to an IL-17-predominant T cell response.
Human SLC15A4 is crucial for TLR-mediated type I interferon production and mitochondrial integrity.
Colorectal Neoplasms
Anti-tumor effects of an antagonistic mAb against the ASCT2 amino acid transporter on KRAS-mutated human colorectal cancer cells.
Antitumor effects of novel mAbs against cationic amino acid transporter 1 (CAT1) on human CRC with amplified CAT1 gene.
Colorectal Cancer-Derived CAT1-Positive Extracellular Vesicles Alter Nitric Oxide Metabolism in Endothelial Cells and Promote Angiogenesis.
Genetic variation in SLC7A2 interacts with calcium and magnesium intakes in modulating the risk of colorectal polyps.
L-type amino acid transporter 1 expression is upregulated and associated with cellular proliferation in colorectal cancer.
Preclinical characterization of (18)F-D-FPHCys, a new amino acid-based PET tracer.
Role of Amino Acid Transporter Expression as a Prognostic Marker in Patients With Surgically Resected Colorectal Cancer.
The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer.
Upregulation of the amino acid transporter ATB0,+ (SLC6A14) in colorectal cancer and metastasis in humans.
Common Cold
The SARS-CoV-2 receptor and other key components of the Renin-Angiotensin-Aldosterone System related to COVID-19 are expressed in enterocytes in larval zebrafish.
Coronavirus Infections
The SARS-CoV-2 receptor and other key components of the Renin-Angiotensin-Aldosterone System related to COVID-19 are expressed in enterocytes in larval zebrafish.
COVID-19
ACE2 Netlas: In silico Functional Characterization and Drug-Gene Interactions of ACE2 Gene Network to Understand Its Potential Involvement in COVID-19 Susceptibility.
ACE2 Netlas: In-silico functional characterization and drug-gene interactions of ACE2 gene network to understand its potential involvement in COVID-19 susceptibility.
Mass Spectrometric Analysis of Urine from COVID-19 Patients for Detection of SARS-CoV-2 Viral Antigen and to Study Host Response.
SNPs at 3'UTR of APOL1 and miR-6741-3p target sites associated with kidney diseases more susceptible to SARS-COV-2 infection: in silco and in vitro studies.
Cystic Fibrosis
Cysteine-scanning mutagenesis provides no evidence for the extracellular accessibility of the nucleotide-binding domains of the multidrug resistance transporter P-glycoprotein.
Structure-function analysis of the histidine permease and comparison with cystic fibrosis mutations.
Cystinuria
Amino acid absorption and homeostasis in mice lacking the intestinal peptide transporter PEPT1.
Amino acid transporters.
Association between M467T and 114 C-->A variants within the SLC3A1 gene and some phenotypical traits in cystinuria patients from Spain.
Carrier subunit of plasma membrane transporter is required for oxidative folding of its helper subunit.
Cloning and expression of a b(0,+)-like amino acid transporter functioning as a heterodimer with 4F2hc instead of rBAT. A new candidate gene for cystinuria.
Cystinuria Associated with Different SLC7A9 Gene Variants in the Cat.
Cystinuria in childhood and adolescence: recommendations for diagnosis, treatment, and follow-up.
Cystinuria phenotyping by oral lysine and arginine loading.
Cystinuria type I: identification of eight new mutations in SLC3A1.
Detection of two novel large deletions in SLC3A1 by semi-quantitative fluorescent multiplex PCR.
Genetic variations of the SLC7A9 gene: allele distribution of 13 polymorphic sites in German cystinuria patients and controls.
Genomic organization of a human cystine transporter gene (SLC3A1) and identification of novel mutations causing cystinuria.
Heterodimeric amino acid transporter glycoprotein domains determining functional subunit association.
Heterodimeric amino acid transporters: molecular biology and pathological and pharmacological relevance.
Heteromeric amino acid transporters explain inherited aminoacidurias.
Identification of 12 novel mutations in the SLC3A1 gene in Swedish cystinuria patients.
Is the broad range amino acid transporter which is induced by a renal microvillar cDNA clone the cystinuria gene?
Luminal heterodimeric amino acid transporter defective in cystinuria.
Mutations in the SLC3A1 gene in cystinuric patients: frequencies and identification of a novel mutation.
Mutations of the basic amino acid transporter gene associated with cystinuria.
Pathophysiology and treatment of cystinuria.
Synergistic mutations in SLC3A1 and SLC7A9 leading to heterogeneous cystinuria phenotypes: pitfalls in the diagnostic workup.
The amino acid transporter asc-1 is not involved in cystinuria.
Type I cystinuria and its genetic basis in a population of Turkish school children.
Cysts
Branched-chain amino acids enhance cyst development in autosomal dominant polycystic kidney disease.
The soybean Rhg1 amino acid transporter gene alters glutamate homeostasis and jasmonic acid-induced resistance to soybean cyst nematode.
Dementia
Aberrant expression of the glutamate transporter excitatory amino acid transporter 1 (EAAT1) in Alzheimer's disease.
Cloning and characterization of HIV-1-inducible astrocyte elevated gene-1, AEG-1.
Demyelinating Diseases
Altered glutamate reuptake in relapsing-remitting and secondary progressive multiple sclerosis cortex: correlation with microglia infiltration, demyelination, and neuronal and synaptic damage.
Aquaporin-4 Autoantibodies From Neuromyelitis Optica Spectrum Disorder Patients Induce Complement-Independent Immunopathologies in Mice.
Diabetes, Gestational
Role of adenosine transport in gestational diabetes-induced L-arginine transport and nitric oxide synthesis in human umbilical vein endothelium.
DiGeorge Syndrome
The gene encoding a cationic amino acid transporter (SLC7A4) maps to the region deleted in the velocardiofacial syndrome.
Dyskinesias
Effects of Combined Bushen Zhichan Recipe and Levodopa in a Rodent Model of Parkinson Disease: Potential Mechanisms.
Encephalitis
Reduced expression of excitatory amino acid transporter 2 and diffuse microglial activation in the cerebral cortex in AIDS cases with or without HIV encephalitis.
Epilepsy
Expression of the glutamate transporters in human temporal lobe epilepsy.
Increased glutamate transporter-associated anion currents cause glial apoptosis in episodic ataxia 6.
Epilepsy, Temporal Lobe
Expression of the glutamate transporters in human temporal lobe epilepsy.
Esophageal Squamous Cell Carcinoma
Expression of L-type amino acid transporter 1 (LAT1) in esophageal carcinoma.
Essential Hypertension
Impaired L-arginine transport and endothelial function in hypertensive and genetically predisposed normotensive subjects.
Mechanistic insights into the link between a polymorphism of the 3'UTR of the SLC7A1 gene and hypertension.
Essential Tremor
Excitatory Amino acid transporter expression in the essential tremor dentate nucleus and cerebellar cortex: A postmortem study.
Fetal Growth Retardation
Association between the activity of the system A amino acid transporter in the microvillous plasma membrane of the human placenta and severity of fetal compromise in intrauterine growth restriction.
Dexamethasone stimulates placental system A transport and trophoblast differentiation in term villous explants.
Downregulation of Placental Amino Acid Transporter Expression and mTORC1 Signaling Activity Contributes to Fetal Growth Retardation in Diabetic Rats.
Effect of fetal growth restriction on system A amino acid transporter activity in the maternal facing plasma membrane of rat syncytiotrophoblast.
Maternal folate deficiency causes inhibition of mTOR signaling, down-regulation of placental amino acid transporters and fetal growth restriction in mice.
Placental-specific Igf2 knockout mice exhibit hypocalcemia and adaptive changes in placental calcium transport.
Regulation of amino acid transporter trafficking by mTORC1 in primary human trophoblast cells is mediated by the ubiquitin ligase Nedd4-2.
Slc7a7 disruption causes fetal growth retardation by downregulating Igf1 in the mouse model of lysinuric protein intolerance.
System A activity and vascular function in the placental-specific Igf2 knockout mouse.
Gastritis
Polyamines Impair Immunity to Helicobacter pylori by Inhibiting L-Arginine Uptake Required for Nitric Oxide Production.
Gastrointestinal Neoplasms
Different Response Profiles of Gastrointestinal Cancer Cells to an L-Type Amino Acid Transporter Inhibitor, JPH203.
Glioblastoma
18F-Fluoroethyl-tyrosine uptake is correlated with amino acid transport and neovascularization in treatment-naive glioblastomas.
Large Amino Acid Transporter 1 Selective Liposomes of l-DOPA Functionalized Amphiphile for Combating Glioblastoma.
Overexpression of SLC7A7 predicts poor progression-free and overall survival in patients with glioblastoma.
Predominant contribution of L-type amino acid transporter to 4-borono-2-(18)F-fluoro-phenylalanine uptake in human glioblastoma cells.
The peroxisome proliferator activated receptor gamma agonist pioglitazone increases functional expression of the glutamate transporter excitatory amino acid transporter 2 (EAAT2) in human glioblastoma cells.
Glioma
"Facilitated" amino acid transport is upregulated in brain tumors.
18F-FDOPA PET/CT Findings in a Patient With Primary Cerebral Amyloidoma.
Amino Acid Metabolism Abnormity and Microenvironment Variation Mediated Targeting and Controlled Glioma Chemotherapy.
Association of three common single nucleotide polymorphisms of SLC7A7 with the development of glioma in a Chinese population.
Correlation of F-18-fluoro-ethyl-tyrosin uptake with vascular and cell density in non-contrast-enhancing gliomas.
Correlation of L: -methyl-(11)C-methionine (MET) uptake with L: -type amino acid transporter 1 in human gliomas.
Enhanced tumor growth elicited by L-type amino acid transporter 1 in human malignant glioma cells.
Genetic variants in SLC7A7 are associated with risk of glioma in a Chinese population.
High expression of L-type amino acid transporter 1 in infiltrating glioma cells.
Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines.
Isoflurane enhances the expression and activity of glutamate transporter type 3 in C6 glioma cells.
Large amino acid transporter 1 mediated glutamate modified docetaxel-loaded liposomes for glioma targeting.
Methylmercury-l-Cysteine targeting L-type amino acid transporter conjugate cytotoxicity on C6 glioma cells.
Targeted alpha therapy using astatine (211At)-labeled phenylalanine: A preclinical study in glioma bearing mice.
The peroxisome proliferator activated receptor gamma agonist pioglitazone increases functional expression of the glutamate transporter excitatory amino acid transporter 2 (EAAT2) in human glioblastoma cells.
The role of CD98 in astrocytic neoplasms.
Glomerulonephritis
Quantitative Proteomics Reveals the Development of HBV-Associated Glomerulonephritis Triggered by the Downregulation of SLC7A7.
Role of amino acid transporter LAT2 in the activation of mTORC1 pathway and the pathogenesis of crescentic glomerulonephritis.
Hartnup Disease
A novel missense mutation in the SLC6A19 gene in a Chinese family with Hartnup disorder.
A protein complex in the brush-border membrane explains a Hartnup disorder allele.
Amino acid absorption and homeostasis in mice lacking the intestinal peptide transporter PEPT1.
Angiotensin-converting enzyme 2 (ACE2) in disease pathogenesis.
Further evidence for allelic heterogeneity in Hartnup disorder.
Hartnup disease presenting as hereditary spastic paraplegia and severe peripheral neuropathy.
Hartnup disorder is caused by mutations in the gene encoding the neutral amino acid transporter SLC6A19.
Hartnup disorder: unraveling the mystery.
Identification and Characterization of Inhibitors of a Neutral Amino Acid Transporter, SLC6A19, Using Two Functional Cell-Based Assays.
Impaired Nutrient Signaling and Body Weight Control in a Na+ Neutral Amino Acid Cotransporter (Slc6a19)-deficient Mouse.
Mutations in SLC6A19, encoding B0AT1, cause Hartnup disorder.
Novel mutation in SLC6A19 causing late-onset seizures in Hartnup disorder.
Persistence of the Common Hartnup Disease D173N Allele in Populations of European Origin.
Rare mutations associating with serum creatinine and chronic kidney disease.
Study of Seizure-Manifested Hartnup Disorder Case Induced By Novel Mutations in SLC6A19.
The serum and glucocorticoid inducible kinases SGK1-3 stimulate the neutral amino acid transporter SLC6A19.
Hemiplegia
Increased glutamate transporter-associated anion currents cause glial apoptosis in episodic ataxia 6.
Hepatoblastoma
S119N Mutation of the E3 Ubiquitin Ligase SPOP Suppresses SLC7A1 Degradation to Regulate Hepatoblastoma Progression.
Hepatolenticular Degeneration
Effect of Copper on l-Cysteine/l-Cystine Influx in Normal Human Erythrocytes and Erythrocytes of Wilson's Disease.
Hernia, Umbilical
A shared vesicular carrier allows synaptic corelease of GABA and glycine.
Homocystinuria
Acute and chronic pancreatitis in patients with inborn errors of metabolism.
Hyperalgesia
Chronic restraint stress decreases glial fibrillary acidic protein and glutamate transporter in the periaqueductal gray matter.
GluN2B N-methyl-D-aspartate receptor and excitatory amino acid transporter 3 are upregulated in primary sensory neurons after 7 days of morphine administration in rats: implication for opiate-induced hyperalgesia.
P2X4-receptor participates in EAAT3 regulation via BDNF-TrkB signaling in a model of trigeminal allodynia.
Sustained Morphine Administration Induces TRPM8-Dependent Cold Hyperalgesia.
Hyperargininemia
Ablation of Arg1 in hematopoietic cells improves respiratory function of lung parenchyma, but not that of larger airways or inflammation in asthmatic mice.
Hyperglycemia
Downregulation of Placental Amino Acid Transporter Expression and mTORC1 Signaling Activity Contributes to Fetal Growth Retardation in Diabetic Rats.
Hypertension
Contribution of SLC7A1 genetic variant to hypertension, the TAMRISK study.
Cyclic strain stimulates L-proline transport in vascular smooth muscle cells.
Identification of a novel polymorphism in the 3'UTR of the L-arginine transporter gene SLC7A1: contribution to hypertension and endothelial dysfunction.
Influence of dietary NaCl on L-arginine transport in the renal medulla.
Mechanistic insights into the link between a polymorphism of the 3'UTR of the SLC7A1 gene and hypertension.
Minisatellite polymorphisms of the SLC6A19: susceptibility in hypertension.
miRNA-145 is associated with spontaneous hypertension by targeting SLC7A1.
Organ specific underexpression renal of Na(+)-dependent B (0)AT1 in the SHR correlates positively with overexpression of NHE3 and salt intake.
Hypotension
Ischemia-induced upregulation of excitatory amino acid transport sites.
Hypothyroidism
Gestational and early postnatal hypothyroidism alters VGluT1 and VGAT bouton distribution in the neocortex and hippocampus, and behavior in rats.
Infections
A glutamate-dependent redox system in blood cells is integral for phagocytosis in Drosophila melanogaster.
Amino acid prodrugs of acyclovir as possible antiviral agents against ocular HSV-1 infections: interactions with the neutral and cationic amino acid transporter on the corneal epithelium.
Cationic amino acid transporter 2 enhances innate immunity during Helicobacter pylori infection.
Envelope-binding domain in the cationic amino acid transporter determines the host range of ecotropic murine retroviruses.
Increase in L-type amino acid transporter 1 expression during cholangiocarcinogenesis caused by liver fluke infection and its prognostic significance.
Kaposi's sarcoma-associated herpesvirus forms a multimolecular complex of integrins (alphaVbeta5, alphaVbeta3, and alpha3beta1) and CD98-xCT during infection of human dermal microvascular endothelial cells, and CD98-xCT is essential for the postentry stage of infection.
L-glutamine Induces Expression of Listeria monocytogenes Virulence Genes.
Microarray analysis reveals the inhibition of intestinal expression of nutrient transporters in piglets infected with porcine epidemic diarrhea virus.
Recombinant adeno-associated virus-mediated high-efficiency, transient expression of the murine cationic amino acid transporter (ecotropic retroviral receptor) permits stable transduction of human HeLa cells by ecotropic retroviral vectors.
Subcellular redistribution of Pit-2 P(i) transporter/amphotropic leukemia virus (A-MuLV) receptor in A-MuLV-infected NIH 3T3 fibroblasts: involvement in superinfection interference.
Susceptibility of muridae cell lines to ecotropic murine leukemia virus and the cationic amino acid transporter 1 viral receptor sequences: implications for evolution of the viral receptor.
The Amino Acid-mTORC1 Pathway Mediates APEC TW-XM-Induced Inflammation in bEnd.3 Cells.
Vibrio parahaemolyticus infection impaired intestinal barrier function and nutrient absorption in Litopenaeus vannamei.
Intellectual Disability
Reduced excitatory amino acid transporter 1 and metabotropic glutamate receptor 5 expression in the cerebellum of fragile X mental retardation gene 1 premutation carriers with fragile X-associated tremor/ataxia syndrome.
The rs113883650 variant of SLC7A5 (LAT1) gene may alter brain phenylalanine content in PKU.
Intestinal Obstruction
Intestinal IMINO transporter SIT1 is not expressed in human newborns.
Iron Deficiencies
Metabolic requirements of NK cells during the acute response against retroviral infection.
Ischemic Stroke
Exercise pre?conditioning alleviates brain damage via excitatory amino acid transporter 2 and extracellular signal?regulated kinase 1/2 following ischemic stroke in rats.
Oxytocin improves ischemic stroke by reducing expression of excitatory amino acid transporter 3 in rat MCAO model.
Kidney Calculi
Cystinuria in childhood and adolescence: recommendations for diagnosis, treatment, and follow-up.
Kidney Diseases
SNPs at 3'UTR of APOL1 and miR-6741-3p target sites associated with kidney diseases more susceptible to SARS-COV-2 infection: in silco and in vitro studies.
Kidney Failure, Chronic
Molecular and cl?n?cal evaluat?on of turk?sh pat?ents w?th lys?nur?c prote?n ?ntolerance.
Language Development Disorders
Lysinuric Protein Intolerance Presenting with Multiple Fractures.
Leiomyoma
Progesterone and Mifepristone Regulate L-Type Amino Acid Transporter 2 and 4F2 Heavy Chain Expression in Uterine Leiomyoma Cells.
Leishmaniasis
Amino acid permease 3 (aap3) coding sequence as a target for Leishmania identification and diagnosis of leishmaniases using high resolution melting analysis.
Leishmaniasis, Visceral
A novel high-affinity arginine transporter from the human parasitic protozoan Leishmania donovani.
Leukemia
A retrovirus uses a cationic amino acid transporter as a cell surface receptor.
Analysis of receptor usage by ecotropic murine retroviruses, using green fluorescent protein-tagged cationic amino acid transporters.
Anemia and perinatal death result from loss of the murine ecotropic retrovirus receptor mCAT-1.
Complementation of a binding-defective retrovirus by a host cell receptor mutant.
Determinant for the inhibition of ecotropic murine leukemia virus infection by N-linked glycosylation of the rat receptor.
Ecotropic murine leukemia virus envelope protein affects interaction of cationic amino acid transporter 1 with clathrin adaptor protein complexes, leading to receptor downregulation.
Enhanced gene expression of the murine ecotropic retroviral receptor and its human homolog in proliferating cells.
Identification of amino acid residues critical for infection with ecotropic murine leukemia retrovirus.
Mutational analysis of the putative receptor-binding domain of Moloney murine leukemia virus glycoprotein gp70.
Receptor-mediated Moloney murine leukemia virus entry can occur independently of the clathrin-coated-pit-mediated endocytic pathway.
Regulation of expression and role of peroxisome proliferator-activated receptors (PPARs) in luminal epithelial and stromal cells of the porcine endometrium.
Seed and vascular expression of a high-affinity transporter for cationic amino acids in Arabidopsis.
Susceptibility of muridae cell lines to ecotropic murine leukemia virus and the cationic amino acid transporter 1 viral receptor sequences: implications for evolution of the viral receptor.
Lung Diseases, Interstitial
Alveolar macrophages from normal subjects lack the NOS-related system y+ for arginine transport.
Lung Neoplasms
Amino acid transporter SLC38A3 promotes metastasis of non-small cell lung cancer cells by activating PDK1.
Aryl hydrocarbon receptor-dependent up-regulation of the heterodimeric amino acid transporter LAT1 (SLC7A5)/CD98hc (SLC3A2) by diesel exhaust particle extract in human bronchial epithelial cells.
ASC amino acid transporter 2, defined by enzyme-mediated activation of radical sources, enhances malignancy of GD2-positive small-cell lung cancer.
CD98 Expression Is Associated with Poor Prognosis in Resected Non-Small-Cell Lung Cancer with Lymph Node Metastases.
Comparison of L-type amino acid transporter 1 expression and L-[3-18F]-?-methyl tyrosine uptake in outcome of non-small cell lung cancer.
Deficient glucose uptake is linked to impaired Glut1 expression upon CD3/CD28 stimulation in memory T cells from pleural effusions secondary to lung cancer.
Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer.
L-type amino acid transporter 1 expression is a prognostic marker in patients with surgically resected stage I non-small cell lung cancer.
Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in surgically resectable stage III non-small cell lung cancer.
Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer.
Relationship between LAT1 expression and response to platinum-based chemotherapy in non-small cell lung cancer patients with postoperative recurrence.
SLC7A7 is a prognostic biomarker correlated with immune infiltrates in non-small cell lung cancer.
Lupus Erythematosus, Systemic
Human SLC15A4 is crucial for TLR-mediated type I interferon production and mitochondrial integrity.
Lymphatic Metastasis
L-Type amino acid transporter 1 (LAT1) expression in lymph node metastasis of gastric carcinoma: Its correlation with size of metastatic lesion and Ki-67 labeling.
Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer.
Lymphoma
Correlation between positron emission tomography findings and glucose transporter 1, 3 and L-type amino acid transporter 1 mRNA expression in primary central nervous system lymphomas.
Malabsorption Syndromes
[Malabsorption syndrome due to membrane transporter abnormality in absorptive epithelial cells]
Malaria
Cationic amino acid transporters play key roles in the survival and transmission of apicomplexan parasites.
Heterologous Expression of a Novel Drug Transporter from the Malaria Parasite Alters Resistance to Quinoline Antimalarials.
Meconium Ileus
SLC6A14, an amino acid transporter, modifies the primary CF defect in fluid secretion.
Melanoma
A Metabolically Stable Boron-Derived Tyrosine Serves as a Theranostic Agent for Positron Emission Tomography Guided Boron Neutron Capture Therapy.
A new treatment for human malignant melanoma targeting L-type amino acid transporter 1 (LAT1): A pilot study in a canine model.
MAPK signaling regulates c-MYC for melanoma cell adaptation to asparagine restriction.
Prognostic significance of L-type amino acid transporter 1 (LAT1) expression in cutaneous melanoma.
Role of L-Type Amino Acid Transporter 1 (LAT1) for the Selective Cytotoxicity of Sesamol in Human Melanoma Cells.
Meningioma
MicroRNA-195 Functions as a Tumor Suppressor by Directly Targeting Fatty Acid Synthase in Malignant Meningioma.
Meningoencephalitis
Impaired expression of excitatory amino acid transporter 2 (EAAT2) and glutamate homeostasis in canine necrotizing meningoencephalitis.
Mesothelioma
L-type amino acid transporter 1 (LAT1) expression in malignant pleural mesothelioma.
Mesothelioma, Malignant
L-type amino acid transporter 1 (LAT1) expression in malignant pleural mesothelioma.
Metabolic Diseases
Update on Lysinuric Protein Intolerance, a Multi-faceted Disease Retrospective cohort analysis from birth to adulthood.
Microcephaly
The amino acid transporter Slc7a5 regulates the mTOR pathway and is required for granule cell development.
Migraine Disorders
Up-regulation of astrocyte excitatory amino acid transporter 2 alleviates central sensitization in a rat model of chronic migraine.
Motor Neuron Disease
Excitatory amino acid transporter 1 and 2 immunoreactivity in the spinal cord in amyotrophic lateral sclerosis.
Expression of the exon 9-skipping form of EAAT2 in astrocytes of rats.
Mouth Neoplasms
Inhibition of L-type amino acid transporter modulates the expression of cell cycle regulatory factors in KB oral cancer cells.
JPH203, an L-type amino acid transporter 1-selective compound, induces apoptosis of YD-38 human oral cancer cells.
The RNA interference of amino acid transporter LAT1 inhibits the growth of KB human oral cancer cells.
Multiple Myeloma
Expression of L-type amino acid transporter 1 (LAT1) as a prognostic and therapeutic indicator in multiple myeloma.
The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma.
Muscle Hypotonia
Molecular and cl?n?cal evaluat?on of turk?sh pat?ents w?th lys?nur?c prote?n ?ntolerance.
Neoplasm Metastasis
Amino acid transporter SLC38A3 promotes metastasis of non-small cell lung cancer cells by activating PDK1.
Effect of miR-122 and its target gene cationic amino acid transporter 1 on colorectal liver metastasis.
Expression of amino acid transporter (LAT1 and 4F2hc) in pulmonary pleomorphic carcinoma.
Expression of L-type amino acid transporter 1 in a rat model of liver metastasis: positive correlation with tumor size.
L-Type amino acid transporter 1 (LAT1) expression in lymph node metastasis of gastric carcinoma: Its correlation with size of metastatic lesion and Ki-67 labeling.
Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer.
Properties of L-type amino acid transporter 1 in epidermal ovarian cancer.
Upregulation of the amino acid transporter ATB0,+ (SLC6A14) in colorectal cancer and metastasis in humans.
Neoplasms
"Facilitated" amino acid transport is upregulated in brain tumors.
(18)F-FBPA as a tumor specific tracer of L-type amino acid transporter 1 (LAT1): PET evaluation in tumor and inflammation compared to (18)F-FDG and (11)C-methionine.
(18)F-FBPA as a tumor-specific probe of L-type amino acid transporter 1 (LAT1): a comparison study with (18)F-FDG and (11)C-Methionine PET.
(18)F-FDG uptake on PET correlates with biological potential in early oral squamous cell carcinoma.
18F-FBPA PET in Sarcoidosis: Comparison to Inflammation-Related Uptake on FDG PET.
18F-FDOPA PET/CT Findings in a Patient With Primary Cerebral Amyloidoma.
A new treatment for human malignant melanoma targeting L-type amino acid transporter 1 (LAT1): A pilot study in a canine model.
A Selective and Slowly Reversible Inhibitor of l-Type Amino Acid Transporter 1 (LAT1) Potentiates Antiproliferative Drug Efficacy in Cancer Cells.
Adenoviral modulation of the tumor-associated system L amino acid transporter, LAT1, alters amino acid transport, cell growth and 4F2/CD98 expressionwith cell-type specific effects in cultured hepatic cells.
Amino acid ester prodrugs conjugated to the ?-carboxylic acid group do not display affinity for the L-type amino acid transporter 1 (LAT1).
Amino Acid Metabolism Abnormity and Microenvironment Variation Mediated Targeting and Controlled Glioma Chemotherapy.
Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics.
Amino acid transporter LAT1 in tumor-associated vascular endothelium promotes angiogenesis by regulating cell proliferation and VEGF-A-dependent mTORC1 activation.
Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer.
Amino Acid transporter-targeted radiotracers for molecular imaging in oncology.
Androgen receptor and nutrient signaling pathways coordinate the demand for increased amino acid transport during prostate cancer progression.
Anti-tumor effects of mAb against l-type amino acid transporter 1 (LAT1) bound to human and monkey LAT1 with dual avidity modes.
Antitumor effect of dimethyl itaconate on thymic carcinoma by targeting LDHA-mTOR axis.
Aryl hydrocarbon receptor (AHR) regulation of L-Type Amino Acid Transporter 1 (LAT-1) expression in MCF-7 and MDA-MB-231 breast cancer cells.
ASC amino acid transporter 2, defined by enzyme-mediated activation of radical sources, enhances malignancy of GD2-positive small-cell lung cancer.
Aspartate-modified doxorubicin on its N-terminal increases drug accumulation in LAT1-overexpressing tumors.
BCH, an inhibitor of system L amino acid transporters, induces apoptosis in cancer cells.
Benzylserine inhibits breast cancer cell growth by disrupting intracellular amino acid homeostasis and triggering amino acid response pathways.
Bifunctional and Unusual Amino Acid ?- or ?-Ester Prodrugs of Nucleoside Analogues for Improved Affinity to ATB0,+ and Enhanced Metabolic Stability: An Application to Floxuridine.
Biomarker Analyses in Patients With Advanced Solid Tumors Treated With the LAT1 Inhibitor JPH203.
Cancer cell specific fluorescent methionine protected gold nanoclusters for in-vitro cell imaging studies.
Cationic amino acid transporter PQLC2 is a potential therapeutic target in gastric cancer.
Cationic amino acid transporter-2 mRNA induction by tumor necrosis factor-alpha in vascular endothelial cells.
CD98 as a novel prognostic indicator for patients with stage III/IV hypopharyngeal squamous cell carcinoma.
Characterization of cationic amino acid transporter and its gene expression in rat hepatic stellate cells in relation to nitric oxide production.
Characterization of the system L amino acid transporter in T24 human bladder carcinoma cells.
Clinical significance of (18)F-?-methyl tyrosine PET/CT for the detection of bone marrow invasion in patients with oral squamous cell carcinoma: comparison with (18)F-FDG PET/CT and MRI.
Clinical significance of coexpression of L-type amino acid transporter 1 (LAT1) and ASC amino acid transporter 2 (ASCT2) in lung adenocarcinoma.
Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in biliary tract cancer.
Clinicopathological Significance of L-type Amino Acid Transporter 1 (LAT1) Expression in Patients with Adenoid Cystic Carcinoma.
Clinicopathological significance of LAT1 and ASCT2 in patients with surgically resected esophageal squamous cell carcinoma.
Comparison of 11C-methionine and 18F-FDG PET-CT for staging and follow-up of pediatric lymphoma.
Comparison of L-type amino acid transporter 1 expression and L-[3-18F]-?-methyl tyrosine uptake in outcome of non-small cell lung cancer.
Control of amino acid transport coordinates metabolic reprogramming in T-cell malignancy.
Correlation of angiogenesis with (18)F-FMT and (18)F-FDG uptake in non-small cell lung cancer.
Correlation of high LAT1 expression with the prognosis of endometrioid carcinoma of the uterine corpus.
Cryo-EM structure of the human L-type amino acid transporter 1 in complex with glycoprotein CD98hc.
Deletion of Amino Acid Transporter ASCT2 (SLC1A5) Reveals an Essential Role for Transporters SNAT1 (SLC38A1) and SNAT2 (SLC38A2) to Sustain Glutaminolysis in Cancer Cells.
Deletion of the amino acid transporter Slc6a14 suppresses tumor growth in spontaneous mouse models of breast cancer.
Deletion of the amino acid transporter Slc6a14 suppresses tumour growth in spontaneous mouse models of breast cancer.
Development of (99m)Tc-EC-tyrosine for Early Detection of Breast Cancer Tumor Response to the Anticancer Drug Melphalan.
Diagnostic usefulness of (18)F-FAMT PET and L-type amino acid transporter 1 (LAT1) expression in oral squamous cell carcinoma.
Different Response Profiles of Gastrointestinal Cancer Cells to an L-Type Amino Acid Transporter Inhibitor, JPH203.
Distribution of LAT1-targeting PET tracer was independent of the tumor blood flow in rat xenograft models of C6 glioma and MIA PaCa-2.
Downregulation of L-type amino acid transporter 1 expression inhibits the growth, migration and invasion of gastric cancer cells.
Effect of miR-122 and its target gene cationic amino acid transporter 1 on colorectal liver metastasis.
Efficacy of LAT1 inhibition as a therapeutic target in esophageal squamous cell carcinoma.
Enhanced tumor growth elicited by L-type amino acid transporter 1 in human malignant glioma cells.
Enhancement of Cancer Cell-Killing Effects of Boron Neutron Capture Therapy by Manipulating the Expression of L-Type Amino Acid Transporter 1.
Establishment of Stable Cell Lines With High Expression of Heterodimers of Human 4F2hc and Human Amino Acid Transporter LAT1 or LAT2 and Delineation of Their Differential Interaction With ?-Alkyl Moieties.
Eugenol attenuates inflammatory response and enhances barrier function during lipopolysaccharide-induced inflammation in the porcine intestinal epithelial cells.
Evaluation of thoracic tumors with (18)F-FMT and (18)F-FDG PET-CT: a clinicopathological study.
Expression of a highly conserved oncofetal gene, TA1/E16, in human colon carcinoma and other primary cancers: homology to Schistosoma mansoni amino acid permease and Caenorhabditis elegans gene products.
Expression of amino acid transporter (LAT1 and 4F2hc) in pulmonary pleomorphic carcinoma.
Expression of Cationic Amino Acid Transporter 2 Is Required for Myeloid-Derived Suppressor Cell-Mediated Control of T Cell Immunity.
Expression of Glutamine Metabolism-Related and Amino Acid Transporter Proteins in Adrenal Cortical Neoplasms and Pheochromocytomas.
Expression of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (4F2hc) in liver tumor lesions of rat models.
Expression of L-type amino acid transporter 1 (LAT1) in neuroendocrine tumors of the lung.
Expression of L-type amino acid transporter 1 in a rat model of liver metastasis: positive correlation with tumor size.
Expression of L-Type Amino Acid Transporter 1 is a Predictive Biomarker of Intravesical Recurrence in Patients with Non-Muscle Invasive Bladder Cancer.
Expression of LAT1 and 4F2hc in Gastroenteropancreatic Neuroendocrine Neoplasms.
Expression profile of the amino acid transporters SLC7A5, SLC7A7, SLC7A8 and the enzyme TDO2 in basal cell carcinoma.
First-in-human phase I study of JPH203, an L-type amino acid transporter 1 inhibitor, in patients with advanced solid tumors.
Fluorine-18-{alpha}-Methyltyrosine Positron Emission Tomography for Diagnosis and Staging of Lung Cancer: A Clinicopathologic Study.
Gene expression profiles in T24 human bladder carcinoma cells by inhibiting an L-type amino acid transporter, LAT1.
Genetic variants in SLC7A7 are associated with risk of glioma in a Chinese population.
Genetic variation in SLC7A2 interacts with calcium and magnesium intakes in modulating the risk of colorectal polyps.
Glioblastoma Exhibits Inter-Individual Heterogeneity of TSPO and LAT1 Expression in Neoplastic and Parenchymal Cells.
Glutamate in cancers: from metabolism to signaling.
Glutaminolysis and carcinogenesis of oral squamous cell carcinoma.
High 18F-FDOPA PET Uptake in Primary Central Nervous System Lymphoma.
High expression of L-type amino acid transporter 1 as a prognostic marker in bile duct adenocarcinomas.
High expression of SLC38A1 predicts poor prognosis in patients with de novo acute myeloid leukemia.
Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines.
IDO Induces Expression of a Novel Tryptophan Transporter in Mouse and Human Tumor Cells.
IL-6 stimulates System A amino acid transporter activity in trophoblast cells through STAT3 and increased expression of SNAT2.
In Vitro Studies to Define the Cell-Surface and Intracellular Targets of Polyarginine-Conjugated Sodium Borocaptate as a Potential Delivery Agent for Boron Neutron Capture Therapy.
In Vivo Loss of Function Screening Reveals Carbonic Anhydrase IX as a Key Modulator of Tumor Initiating Potential in Primary Pancreatic Tumors.
Increase in L-type amino acid transporter 1 expression during cholangiocarcinogenesis caused by liver fluke infection and its prognostic significance.
Increased expression of system large amino acid transporter (LAT)-1 mRNA is associated with invasive potential and unfavorable prognosis of human clear cell renal cell carcinoma.
Increased tryptophan transport in epileptogenic dysembryoplastic neuroepithelial tumors.
Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer.
Inhibition of the amino-acid transporter LAT1 demonstrates anti-neoplastic activity in medulloblastoma.
Interaction of tryptophan derivatives with SLC6A14 (ATB0,+) reveals the potential of the transporter as a drug target for cancer chemotherapy.
Investigation of the role of transporters on the hepatic elimination of an LAT1 selective inhibitor JPH203.
JPH203, a newly developed anti-cancer drug, shows a preincubation inhibitory effect on L-type amino acid transporter 1 function.
JPH203, a selective L-type amino acid transporter 1 inhibitor, induces mitochondria-dependent apoptosis in Saos2 human osteosarcoma cells.
JPH203, an L-type amino acid transporter 1-selective compound, induces apoptosis of YD-38 human oral cancer cells.
L-Type Amino Acid Transporter 1 (LAT1) Expression in Canine Mammary Gland Tumors.
L-type amino acid transporter 1 (LAT1) expression in malignant pleural mesothelioma.
L-type amino acid transporter 1 (LAT1) is frequently expressed in thymic carcinomas but is absent in thymomas.
L-type amino acid transporter 1 (LAT1)-utilizing efflux transporter inhibitors can improve the brain uptake and apoptosis-inducing effects of vinblastine in cancer cells.
L-Type amino acid transporter 1 (LAT1)-utilizing prodrugs are carrier-selective despite having low affinity for organic anion transporting polypeptides (OATPs).
L-type amino acid transporter 1 (LAT1): A new therapeutic target for canine mammary gland tumour.
l-type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms.
L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors.
L-type amino acid transporter 1 expression in esophageal carcinogenesis according to WHO and Japanese classifications of intraepithelial neoplasia.
L-type amino acid transporter 1 expression is upregulated and associated with cellular proliferation in colorectal cancer.
L-type amino acid transporter 1 inhibitors inhibit tumor cell growth.
L-type amino-acid transporter 1 expression predicts the response to preoperative hyperthermo-chemoradiotherapy for advanced rectal cancer.
LAT-1 and GLUT-1 Carrier Expression and Its Prognostic Value in Gastroenteropancreatic Neuroendocrine Tumors.
LAT1 expression is closely associated with hypoxic markers and mTOR in resected non-small cell lung cancer.
LAT1-Targeting Thermoresponsive Fluorescent Polymer Probes for Cancer Cell Imaging.
Macrophage-Derived IL1? and TNF? Regulate Arginine Metabolism in Neuroblastoma.
Metabolism and Pharmacokinetic Studies of JPH203, an L-Amino Acid Transporter 1 (LAT1) Selective Compound.
Metformin enhances anti-tumor effect of L-type amino acid transporter 1 (LAT1) inhibitor.
Molecular mechanisms of necrosis in glioblastoma: The role of gutamate excitotoxicity.
Neuromyelitis optica - an update: 2007-2009.
Novel 18F-Labeled ?-Methyl-Phenylalanine Derivative with High Tumor Accumulation and Ideal Pharmacokinetics for Tumor-Specific Imaging.
Nutritional Stress Induced by Tryptophan-Degrading Enzymes Results in ATF4-Dependent Reprogramming of the Amino Acid Transporter Profile in Tumor Cells.
Oligodendroglioma in 68Ga-PSMA-11 and 18F-Fluciclovine PET/CT.
Overexpression of SLC7A7 predicts poor progression-free and overall survival in patients with glioblastoma.
Preclinical assessment of early tumor response after irradiation by positron emission tomography with 2-amino-[3-¹¹C]isobutyric acid.
Preclinical characterization of (18)F-D-FPHCys, a new amino acid-based PET tracer.
Preclinical evaluation of new ?-radionuclide therapy targeting LAT1: 2-[211At]astato-?-methyl-L-phenylalanine in tumor-bearing model.
Production and characterization of highly tumor-specific rat monoclonal antibodies recognizing the extracellular domain of human L-type amino-acid transporter 1.
Prognostic impact of LAT1 and CD98 expression in cutaneous angiosarcoma.
Prognostic significance of L-type amino acid transporter 1 (LAT1) expression in patients with ovarian tumors.
Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer.
Prognostic Value of L-Type Amino Acid Transporter 1 (LAT1) in Various Cancers: A Meta-Analysis.
Prognostic value of LAT-1 status in solid cancer: A systematic review and meta-analysis.
Proteomics and phosphoproteomics reveal key regulators associated with cytostatic effect of amino acid transporter LAT1 inhibitor.
Radioiodinated 4-iodo-L-meta-tyrosine, a system L selective artificial amino acid: molecular design and transport characterization in Chinese hamster ovary cells (CHO-K1 cells).
Reciprocal regulation of amino acid import and epigenetic state through Lat1 and EZH2.
Reevaluating the Substrate Specificity of the L-Type Amino Acid Transporter (LAT1).
Relationship between LAT1 expression and resistance to chemotherapy in pancreatic ductal adenocarcinoma.
Rigorous sampling of docking poses unveils binding hypothesis for the halogenated ligands of L-type Amino acid Transporter 1 (LAT1).
Role of Amino Acid Transporter Expression as a Prognostic Marker in Patients With Surgically Resected Colorectal Cancer.
Selective induction of a cationic amino acid transporter by tumor necrosis factor-alpha in vascular endothelium.
Short-term arginine deprivation results in large-scale modulation of hepatic gene expression in both normal and tumor cells: bioinformatic analysis.
Significant relationship between the LAT1 expression pattern and chemoresistance in ovarian clear cell carcinoma.
Single-ligand dual-targeting irinotecan liposomes: Control of targeting ligand display by pH-responsive PEG-shedding strategy to enhance tumor-specific therapy and attenuate toxicity.
SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer.
SLC6A14, a Na+/Cl--coupled amino acid transporter, functions as a tumor promoter in colon and is a target for Wnt signaling.
SLC7A7 is a prognostic biomarker correlated with immune infiltrates in non-small cell lung cancer.
Specific transport of 3-fluoro-l-?-methyl-tyrosine by LAT1 explains its specificity to malignant tumors in imaging.
Structure-activity relationship of a novel series of inhibitors for cancer type transporter L-type amino acid transporter 1 (LAT1).
Structure-based ligand discovery for the Large-neutral Amino Acid Transporter 1, LAT-1.
Synthesis and Biological Evaluation of O-[3-(18)F-fluoropropyl]- ? -methyl Tyrosine in Mesothelioma-Bearing Rodents.
Synthesis and biological properties of radiohalogenated ?,?-disubstituted amino acids for PET and SPECT imaging of amino acid transporters (AATs).
Synthesis and preliminary evaluation of a novel glutamine derivative: (2S,4S)4-[18F]FEBGln.
Synthesis and radiolabelling of DOTA-linked glutamine analogues with ??,??Ga as markers for increased glutamine metabolism in tumour cells.
System a amino acid transport-targeted brain and systemic tumor PET imaging agents 2-amino-3-[(18)F]fluoro-2-methylpropanoic acid and 3-[(18)F]fluoro-2-methyl-2-(methylamino)propanoic acid.
TA1/LAT-1/CD98 light chain and system L activity, but not 4F2/CD98 heavy chain, respond to arginine availability in rat hepatic cells. Loss Of response in tumor cells.
Targeted efflux transporter inhibitors - A solution to improve poor cellular accumulation of anti-cancer agents.
Targeted Suppression and Knockout of ASCT2 or LAT1 in Epithelial and Mesenchymal Human Liver Cancer Cells Fail to Inhibit Growth.
Targeting tumor highly-expressed LAT1 transporter with amino acid-modified nanoparticles: Toward a novel active targeting strategy in breast cancer therapy.
The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours.
The Effects of Prodrug Size and a Carbonyl Linker on l-Type Amino Acid Transporter 1-Targeted Cellular and Brain Uptake.
The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5).
The impact of L-type amino acid transporter 1 (LAT1) in human hepatocellular carcinoma.
The L-type amino acid transporter LAT1 inhibits osteoclastogenesis and maintains bone homeostasis through the mTORC1 pathway.
The L-Type Amino Acid Transporter LAT1-An Emerging Target in Cancer.
The Regulation and Function of the L-Type Amino Acid Transporter 1 (LAT1) in Cancer.
The RNA interference of amino acid transporter LAT1 inhibits the growth of KB human oral cancer cells.
The role of L-type amino acid transporter 1 in human tumors.
Thymol improves barrier function and attenuates inflammatory responses in porcine intestinal epithelial cells during lipopolysaccharide (LPS)-induced inflammation.
Trafficking to the Cell Surface of Amino Acid Transporter SLC6A14 Upregulated in Cancer Is Controlled by Phosphorylation of SEC24C Protein by AKT Kinase.
Transport of 3-fluoro-l-?-methyl-tyrosine (FAMT) by organic ion transporters explains renal background in [(18)F]FAMT positron emission tomography.
Transport of 3-Fluoro-L-?-Methyl-Tyrosine by Tumor-Upregulated L-Type Amino Acid Transporter 1: A Cause of the Tumor Uptake in PET.
Treatment strategy of a huge ameloblastic carcinoma.
Tryptophan conjugated magnetic nanoparticles for targeting tumors overexpressing indoleamine 2,3 dioxygenase (IDO) and L-type amino acid transporter.
Tyrosine modified irinotecan-loaded liposomes capable of simultaneously targeting LAT1 and ATB0,+ for efficient tumor therapy.
Tyrosine-Chlorambucil Conjugates Facilitate Cellular Uptake through L-Type Amino Acid Transporter 1 (LAT1) in Human Breast Cancer Cell Line MCF-7.
Ultrastructural immunohistochemical study of L-type amino acid transporter 1-4F2 heavy chain in tumor microvasculatures of N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) induced rat bladder carcinoma.
Unique and selective expression of L-amino acid transporter 1 in human tissue as well as being an aspect of oncofetal protein.
Xenopus slc7a5 is essential for notochord function and eye development.
[Drug Discovery Targeting an Amino Acid Transporter for Diagnosis and Therapy].
[Effect of SLC7A5 on the proliferation of tumor cells and its relationship with transforming growth factor-?1 ?signal pathway].
¹?F-FAMT uptake correlates with tumor proliferative activity in oral squamous cell carcinoma: comparative study with ¹?F-FDG PET and immunohistochemistry.
Nervous System Diseases
EAAT2 regulation and splicing: relevance to psychiatric and neurological disorders.
Epigenetic Regulation of Excitatory Amino Acid Transporter 2 in Neurological Disorders.
Manganese-induced reactive oxygen species activate I?B kinase to upregulate YY1 and impair glutamate transporter EAAT2 function in human astrocytes in vitro.
The L-type amino acid transporter LAT1 inhibits osteoclastogenesis and maintains bone homeostasis through the mTORC1 pathway.
Variants of the EAAT2 Glutamate Transporter Gene Promoter Are Associated with Cerebral Palsy in Preterm Infants.
Neurodegenerative Diseases
Utilizing an Animal Model to Identify Brain Neurodegeneration-Related Biomarkers in Aging.
Neuroendocrine Tumors
Expression of L-type amino acid transporter 1 (LAT1) in neuroendocrine tumors of the lung.
Overexpression of L-Type Amino Acid Transporter 1 (LAT1) and 2 (LAT2): Novel Markers of Neuroendocrine Tumors.
Neurologic Manifestations
A novel missense mutation in the SLC6A19 gene in a Chinese family with Hartnup disorder.
Neuromyelitis Optica
Evidence against cellular internalization in vivo of NMO-IgG, aquaporin-4, and excitatory amino acid transporter 2 in neuromyelitis optica.
Obesity
Development of Biomarkers for Inhibition of SLC6A19 (B?AT1)-A Potential Target to Treat Metabolic Disorders.
Polymorphisms in the amino acid transporter solute carrier family 6 (neurotransmitter transporter) member 14 gene contribute to polygenic obesity in French Caucasians.
The Adipose Tissue-Derived Secretome (ADS) in Obesity Uniquely Induces L-Type Amino Acid Transporter 1 (LAT1) and mTOR Signaling in Estrogen-Receptor-Positive Breast Cancer Cells.
The SLC6A14 gene shows evidence of association with obesity.
Obstetric Labor, Premature
Synthetic glucocorticoid reduces human placental system a transport in women treated with antenatal therapy.
Ocular Hypertension
5-HT1A Receptor Agonist Promotes Retinal Ganglion Cell Function by Inhibiting OFF-Type Presynaptic Glutamatergic Activity in a Chronic Glaucoma Model.
Osteoporosis
Lysinuric Protein Intolerance Presenting with Multiple Fractures.
Molecular and cl?n?cal evaluat?on of turk?sh pat?ents w?th lys?nur?c prote?n ?ntolerance.
Slc7a7 disruption causes fetal growth retardation by downregulating Igf1 in the mouse model of lysinuric protein intolerance.
y+LAT1 and y+LAT2 contribution to arginine uptake in different human cell models: Implications in the pathophysiology of Lysinuric Protein Intolerance.
Osteosarcoma
JPH203, a selective L-type amino acid transporter 1 inhibitor, induces mitochondria-dependent apoptosis in Saos2 human osteosarcoma cells.
Ovarian Neoplasms
Impact of system L amino acid transporter 1 (LAT1) on proliferation of human ovarian cancer cells: a possible target for combination therapy with anti-proliferative aminopeptidase inhibitors.
Properties of L-type amino acid transporter 1 in epidermal ovarian cancer.
Pancreatic Neoplasms
Amino acid transporter SLC6A14 is a novel and effective drug target for pancreatic cancer.
Long noncoding RNA GSTM3TV2 upregulates LAT2 and OLR1 by competitively sponging let-7 to promote gemcitabine resistance in pancreatic cancer.
Synergism between SLC6A14 blockade and gemcitabine in pancreactic cancer: a 1H-NMR-based metabolomic study in pancreatic cancer cells.
Synthesis of Gemcitabine-Threonine Amide Prodrug Effective on Pancreatic Cancer Cells with Improved Pharmacokinetic Properties.
Papilledema
Mineralocorticoid Receptor Pathway and its Antagonism in a Model of Diabetic Retinopathy.
Paralysis
Regulation of internal ribosomal entry site-mediated translation by phosphorylation of the translation initiation factor eIF2alpha.
Parkinson Disease
An active transport system in the blood-brain barrier may reduce levodopa availability.
Effects of Combined Bushen Zhichan Recipe and Levodopa in a Rodent Model of Parkinson Disease: Potential Mechanisms.
Manganese-induced reactive oxygen species activate I?B kinase to upregulate YY1 and impair glutamate transporter EAAT2 function in human astrocytes in vitro.
MicroRNA-128 Protects Dopamine Neurons from Apoptosis and Upregulates the Expression of Excitatory Amino Acid Transporter 4 in Parkinson's Disease by Binding to AXIN1.
Reduction of L-type amino acid transporter 1 mRNA expression in brain capillaries in a mouse model of Parkinson's disease.
Secondary carbamate linker can facilitate the sustained release of dopamine from brain-targeted prodrug.
Phenylketonurias
The rs113883650 variant of SLC7A5 (LAT1) gene may alter brain phenylalanine content in PKU.
Pheochromocytoma
18F-FDOPA PET and PET/CT accurately localize pheochromocytomas.
Expression of Glutamine Metabolism-Related and Amino Acid Transporter Proteins in Adrenal Cortical Neoplasms and Pheochromocytomas.
Pituitary Neoplasms
L-type amino acid transporter 1, LAT1, in growth hormone-producing pituitary tumor cells.
Placental Insufficiency
Regulation of amino acid transporters by adenoviral-mediated human insulin-like growth factor-1 in a mouse model of placental insufficiency in vivo and the human trophoblast line BeWo in vitro.
Porphyria, Acute Intermittent
Acute and chronic pancreatitis in patients with inborn errors of metabolism.
Porphyrias
Acute and chronic pancreatitis in patients with inborn errors of metabolism.
Posterior Leukoencephalopathy Syndrome
Neuromyelitis optica - an update: 2007-2009.
Pre-Eclampsia
L-Arginine transport across the basal plasma membrane of the syncytiotrophoblast of the human placenta from normal and preeclamptic pregnancies.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Function of SLC7A7 in T-Cell Acute Lymphoblastic Leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Control of amino acid transport coordinates metabolic reprogramming in T-cell malignancy.
Prostatic Neoplasms
Amino acid transporter expression and 18F-FACBC uptake at PET in primary prostate cancer.
Androgen receptor and nutrient signaling pathways coordinate the demand for increased amino acid transport during prostate cancer progression.
Correlation between 18F-1-amino-3-fluorocyclobutane-1-carboxylic acid (18F-fluciclovine) uptake and expression of alanine-serine-cysteine-transporter 2 (ASCT2) and L-type amino acid transporter 1 (LAT1) in primary prostate cancer.
EGF-activated PI3K/Akt signalling coordinates leucine uptake by regulating LAT3 expression in prostate cancer.
Functional analysis of LAT3 in prostate cancer: Its downstream target and relationship with androgen receptor.
L-type amino acid transporter 1 expression is highly correlated with Gleason score in prostate cancer.
Preclinical characterization of (18)F-D-FPHCys, a new amino acid-based PET tracer.
Prostate Cancer Cells in Different Androgen Receptor Status Employ Different Leucine Transporters.
Replication-incompetent gammaretroviral and lentiviral vector-based insertional mutagenesis screens identify prostate cancer progression genes.
SLFN5 Regulates LAT1-Mediated mTOR Activation in Castration-Resistant Prostate Cancer.
Synthesis and evaluation of an 18F-labeled boramino acid analog of aminosuberic acid for PET imaging of the antiporter system xC
[(14)C]Fluciclovine (alias anti-[(14)C]FACBC) uptake and ASCT2 expression in castration-resistant prostate cancer cells.
Psoriasis
Targeting L-type amino acid transporter 1 in innate and adaptive T cells efficiently controls skin inflammation.
Pulmonary Alveolar Proteinosis
Dysfunction in macrophage toll-like receptor signaling caused by an inborn error of cationic amino acid transport.
Increased NO production in lysinuric protein intolerance.
Pulmonary Fibrosis
The cationic amino acid transporter 2 is induced in inflammatory lung models and regulates lung fibrosis.
Rectal Neoplasms
L-type amino-acid transporter 1 expression predicts the response to preoperative hyperthermo-chemoradiotherapy for advanced rectal cancer.
Renal Insufficiency
Increased NO production in lysinuric protein intolerance.
y+LAT1 and y+LAT2 contribution to arginine uptake in different human cell models: Implications in the pathophysiology of Lysinuric Protein Intolerance.
Retinoblastoma
Differential Expression of Folate Receptor-Alpha, Sodium-Dependent Multivitamin Transporter, and Amino Acid Transporter (B ((0, +))) in Human Retinoblastoma (Y-79) and Retinal Pigment Epithelial (ARPE-19) Cell Lines.
Expression profiling analyses of gonadotropin responses and tumor development in the absence of inhibins.
Retroviridae Infections
GRB2 interaction with the ecotropic murine leukemia virus receptor, mCAT-1, controls virus entry and is stimulated by virus binding.
Sarcoma
Arginine auxotrophic gene signature in paediatric sarcomas and brain tumours provides a viable target for arginine depletion therapies.
The use of protein-DNA, chromatin immunoprecipitation, and transcriptome arrays to describe transcriptional circuits in the dehydrated male rat hypothalamus.
Sarcoma, Kaposi
Production of brown/yellow patches in the SLC7A11 transgenic sheep via testicular injection of transgene.
Upregulation of xCT by KSHV-encoded microRNAs facilitates KSHV dissemination and persistence in an environment of oxidative stress.
Seizures
Caffeine-induced inhibition of the activity of glutamate transporter type 3 expressed in Xenopus oocytes.
Early rapid rise in EAAT2 expression follows the period of maximal seizure susceptibility in human brain.
Effects of progesterone on glutamate transporter 2 and gamma-aminobutyric acid transporter 1 expression in the developing rat brain after recurrent seizures.
Expression of the glutamate transporters in human temporal lobe epilepsy.
Network-Related Changes in Neurotransmitters and Seizure Propagation During Rodent Epileptogenesis.
Nicotine decreases the activity of glutamate transporter type 3.
Novel mutation in SLC6A19 causing late-onset seizures in Hartnup disorder.
Plasticity of excitatory amino acid transporters in experimental epilepsy.
Single step nanospray drying preparation technique of gabapentin-loaded nanoparticles-mediated brain delivery for effective treatment of PTZ-induced seizures.
Study of Seizure-Manifested Hartnup Disorder Case Induced By Novel Mutations in SLC6A19.
The amino acid transporter Slc7a5 regulates the mTOR pathway and is required for granule cell development.
Sepsis
Altered L-arginine/nitric oxide synthase/nitric oxide pathway in the vascular adventitia of rats with sepsis.
Sepsis-induced changes in amino acid transporters and leucine signaling via mTOR in skeletal muscle.
Spinal Cord Injuries
Up-regulation of L type amino acid transporter 1 after spinal cord injury in rats.
Squamous Cell Carcinoma of Head and Neck
ASCT2 (SLC1A5)-dependent glutamine uptake is involved in the progression of head and neck squamous cell carcinoma.
Diagnostic usefulness of (18)F-FAMT PET and L-type amino acid transporter 1 (LAT1) expression in oral squamous cell carcinoma.
Expression of Amino Acid Transporters (LAT1 and ASCT2) in Patients with Stage III/IV Laryngeal Squamous Cell Carcinoma.
Expression of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (4F2hc) in oral squamous cell carcinoma and its precusor lesions.
System L amino acid transporter inhibitor enhances anti-tumor activity of cisplatin in a head and neck squamous cell carcinoma cell line.
Starvation
Nutrient availability regulates proline/alanine transporters in Trypanosoma brucei.
Nutritional Stress Induced by Amino Acid Starvation Results in Changes for Slc38 Transporters in Immortalized Hypothalamic Neuronal Cells and Primary Cortex Cells.
PheP, a putative amino acid permease of Staphylococcus aureus, contributes to survival in vivo and during starvation.
Proteasomal modulation of cellular SNAT2 (SLC38A2) abundance and function by unsaturated fatty acid availability.
Protein characterization of NA+-independent system L amino acid transporter 3 in mice: a potential role in supply of branched-chain amino acids under nutrient starvation.
Serotonin signaling mediates protein valuation and aging.
The fission yeast ?-arrestin-like protein Any1 is involved in TSC-Rheb signaling and the regulation of amino acid transporters.
The gene encoding the major proline transporter of Aspergillus nidulans is upregulated during conidiospore germination and in response to proline induction and amino acid starvation.
The hnRNA-binding proteins hnRNP L and PTB are required for efficient translation of the Cat-1 arginine/lysine transporter mRNA during amino acid starvation.
The N-terminal domain of the yeast permease Bap2p plays a role in its degradation.
Status Epilepticus
Excitatory amino acid transporter 2 downregulation correlates with thalamic neuronal death following kainic acid-induced status epilepticus in rat.
Stomach Neoplasms
Cationic amino acid transporter PQLC2 is a potential therapeutic target in gastric cancer.
Downregulation of L-type amino acid transporter 1 expression inhibits the growth, migration and invasion of gastric cancer cells.
High L-Type Amino Acid Transporter 1 Levels Are Associated with Chemotherapeutic Resistance in Gastric Cancer Patients.
Subarachnoid Hemorrhage
Ceftriaxone alleviates early brain injury after subarachnoid hemorrhage by increasing excitatory amino acid transporter 2 expression via the PI3K/Akt/NF-?B signaling pathway.
Teratocarcinoma
Expression profiling analyses of gonadotropin responses and tumor development in the absence of inhibins.
Thymoma
18F-Fluciclovine Uptake in Thymoma Demonstrated on PET/MRI.
L-type amino acid transporter 1 (LAT1) is frequently expressed in thymic carcinomas but is absent in thymomas.
L-Type Amino Acid Transporter 1 Immunoreactivity as a Possible Diagnostic and Prognostic Marker of Thymic Carcinoma.
Triple Negative Breast Neoplasms
Correlation of L-type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis.
PET Imaging of L-Type Amino Acid Transporter (LAT1) and Cystine-Glutamate Antiporter (xc-) with [18F]FDOPA and [18F]FSPG in Breast Cancer Models.
Trypanosomiasis, African
Functional Complementation Analyses Reveal that the Single PRAT Family Protein of Trypanosoma brucei Is a Divergent Homolog of Tim17 in Saccharomyces cerevisiae.
Tuberculosis
Mycobacterium tuberculosis nitrogen assimilation and host colonization require aspartate.
Urea Cycle Disorders, Inborn
[Clinical features of children with lysinuric protein intolerance and SLC7A7 gene mutation: an analysis of 3 cases].
Urinary Bladder Neoplasms
Expression of L-Type Amino Acid Transporter 1 is a Predictive Biomarker of Intravesical Recurrence in Patients with Non-Muscle Invasive Bladder Cancer.
Urinary Calculi
Synergistic mutations in SLC3A1 and SLC7A9 leading to heterogeneous cystinuria phenotypes: pitfalls in the diagnostic workup.
Yellow Fever
AaCAT1 of the Yellow Fever Mosquito, Aedes aegypti: A NOVEL HISTIDINE-SPECIFIC AMINO ACID TRANSPORTER FROM THE SLC7 FAMILY.